We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04559022
Recruitment Status : Active, not recruiting
First Posted : September 22, 2020
Last Update Posted : July 29, 2022
Sponsor:
Information provided by (Responsible Party):
Jeffrey M. Kenkel, University of Texas Southwestern Medical Center

Brief Summary:
This single-center, clinical trial consists of a one autologous fat grafting treatment followed by 3-month and 6-month post-treatment visits in order to assess the efficacy of fat grafting when used by men and women with facial acne scars.

Condition or disease Intervention/treatment Phase
Acne Scars - Mixed Atrophic and Hypertrophic Acne Procedure: Fat Grafting Not Applicable

Detailed Description:
This investigation, pilot study will evaluate the safety and efficacy of autologous fat grafting for the treatment of acne scarring. Overall assessment of clinical outcome and safety will be based clinic visits and evaluation of pre- and post- procedural photos. In conjunction with standard and close-up photography, we will also be using 3D imaging, cross-polarized imaging, UV imaging, high-resolution ultrasonography, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements. Additionally, we will be utilizing 0.33 mm skin biopsies to assess histological and genetic changes that occur below the skin surface as a result of this treatment. The subject's assessment of satisfaction will be characterized using a non-parametric assessment scale at each follow-up period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
Actual Study Start Date : October 30, 2020
Actual Primary Completion Date : June 10, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Scars

Arm Intervention/treatment
Fat Grafting for Acne Scar Treatment
This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
Procedure: Fat Grafting
This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.




Primary Outcome Measures :
  1. Facial Photograph Assessments [ Time Frame: Baseline and 6 Months ]

    Photographs will be used to evaluate efficacy of treatment. The photographs from final visit will be compared to their baseline photographs and visually evaluated by the study team.

    Acne scars on patients will be assessed using the Clinician's Global Assessment Improvement Scale (CGAIS)


  2. Change in Volume (MiraVex) [ Time Frame: Baseline and 6 Months ]
    MiraVex will be used to assess changes in volume of the subjects facial acne scars.

  3. VISIA Complexion Analysis: Change in Spots [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure spots

  4. VISIA Complexion Analysis: Change in wrinkles [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure wrinkles.

  5. VISIA Complexion Analysis: Change in Texture [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure texture.

  6. VISIA Complexion Analysis: Change in Pores [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure pores.

  7. VISIA Complexion Analysis: Change in UV Spots [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure UV spots

  8. VISIA Complexion Analysis: Change in Brown Spots [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure brown spots.

  9. VISIA Complexion Analysis: Change in Red Areas [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure red areas

  10. VISIA Complexion Analysis: Change in Porphyrins [ Time Frame: Baseline, 3 Months, and 6 Months ]
    The VISIA will be used to objectively measure porphyrins.

  11. Transepidermal Water Loss (TEWL) Measurements: Change in Epidermal Layer [ Time Frame: Baseline, 3 Months and 6 Motnhs ]
    Measurements will be used to evaluate barrier function of the skin epidermal layer to determine progress of epidermal healing after treatment.

  12. High Resolution Ultrasound: Change Dermal Thickness [ Time Frame: Baseline, 3 Months and 6 Months ]
    Dermal thickness will be measured via high resolution ultrasound prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame.

  13. High Resolution Ultrasound: Change in Epidermal Thickness [ Time Frame: Baseline, 3 Months and 6 Months ]
    Epidermal thickness will be measured via high resolution ultrasound prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame.

  14. BTC2000: Change in Skin Elasticity [ Time Frame: Baseline, 3 Months and 6 Months ]
    Skin Elasticity will be measured via BTC2000 prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame.

  15. BTC 2000: Change in Skin Laxity [ Time Frame: Baseline, 3 Months and 6 Months ]
    Skin Laxity will be measured via BTC2000 prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame.

  16. Histological Analysis [ Time Frame: Baseline, 3 Months and 6 Months ]
    Relative changes in protein abundance in biopsies taken at post treatment compare to control or entreated group will be quantified using an image processing software based on fluorescence signal intensity. The change from baseline was calculated at each time frame.

  17. Gene Expression [ Time Frame: Baseline, 3 Months and 6 Months ]
    Biopsies of the treated are will be taken prior to treatment and post treatment for gene expression analysis. This analysis will identify gene expression related to collagen formation and increased cell turnover.

  18. Change in Blood Flow [ Time Frame: Baseline, 3 Months and 6 Months ]
    Blood Flow will be measured via optical coherence tomography prior to treatment (baseline), 3 months and 6 months post treatment.

  19. High Resolution Ultrasound: Change in Epidermal Density [ Time Frame: Baseline, 3 Months, and 6 Months ]
    Epidermal thickness will be masured via high resolution ultrasound prior to treatment (baseline), 3 months and 6 months post treatment. The change from baseline was calculated at each time frame.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Men and women 18 to 50 years of age having general good health.
  2. Individuals deemed by the Investigator to have a significant amount acne scarring on the face and that desire correction of this condition.
  3. Individuals willing to withhold aesthetic therapies to the areas of the hand being treated or judged to potentially impact results by the Investigator (e.g. soft tissue fillers and/or any resurfacing procedures, botulinum toxin, injectable fillers, microdermabrasion, IPL (intense pulsed light), peels, laser treatments, and tightening treatments, etc.) for the duration of the study. Waxing and threading is allowed but no laser treatments outside of the study.
  4. Individuals that are willing to provide written informed consent and are able to read, speak, write, and understand English.
  5. Individuals willing to sign a photography release.
  6. Willingness to cooperate and participate by following study requirements for the duration of the study and to report any changes in health status or medications, adverse event symptoms, or reactions immediately.

Exclusion Criteria:

  1. Individuals diagnosed with known allergies to general skin care products.
  2. Individuals who have presence of an active systemic or local skin disease that may affect wound healing.
  3. Individuals with sensitivity to topical lidocaine.
  4. Individuals who have physical or psychological conditions unacceptable to the Investigator.
  5. Individuals who have a recent history of significant trauma to the areas to be treated (< 6 months).
  6. Individuals who have severe or cystic active and clinically significant acne on the area(s) to be treated. Clinically significant acne is defined as a subject whom has > 5 active inflammatory acne lesions (including acne conglobate, nodules, or cysts) in either the right or left treatment area.
  7. Individuals who have a recent or current history of inflammatory skin disease, infection, unhealed wound or clinically significant acne in the proposed treatment areas.
  8. Individuals who have a history of systemic granulomatous diseases, active or inactive, (e.g. Sarcoid, Wegeners, TB, etc.) or connective tissue diseases (e.g. lupus, dermatomyositis, etc.).
  9. Individuals who currently have or have a history of hypertrophic scars, or keloid scars.
  10. Individuals who currently have cancerous or pre-cancerous lesions in the areas to be treated and/or with a history of skin cancer.
  11. Individuals who have the inability to understand instructions or to give informed consent.
  12. Individuals who have had microdermabrasion or glycolic acid treatment to the treatment area(s) within one month prior to study participation or who will have this treatment during the study.
  13. Individuals who have a history of chronic drug or alcohol abuse.
  14. Individuals undergoing concurrent therapy that, in the Investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
  15. Individuals who, in the Investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.
  16. Individuals who have a history of the following cosmetic treatments in the area(s) to be treated:

    • Skin tightening procedure within the past year;
    • Injectable filler of any type within the past:

      • 12 months for Hyaluronic acid fillers (e.g. Restylane)
      • 12 months for Ca Hydroxyapatite fillers (e.g. Radiesse)
      • 24 months for Poly-L-Lactic acid fillers (e.g. Sculptra)
      • Ever for permanent fillers (e.g. Silicone, ArteFill)
    • Neurotoxins within the past three months;
    • Ablative resurfacing laser treatment;
    • Non-ablative, rejuvenative laser or light treatment within the past six months;
    • Surgical dermabrasion;
    • Had a chemical peel or dermabrasion, of the dorsum of the hand within four weeks
  17. Individuals with a history of using the following prescription medications:

    • Accutane or other systemic retinoids within the past six months;
    • Topical Retinoids within the past two weeks;
    • Prescription strength skin lightening devices (e.g. hydroquinone, tretinoin, AHA, BHA and polyhydroxy acids, 4-hydroxyanisole alone or in combination with tretinoin, etc.) within four months;
    • Any anti-wrinkle, skin lightening devices, or any other device or topical or systemic medication known to affect skin aging or dyshcromia (devices containing alpha/beta/poly-hydroxy acids, vitamin C, soy, Q-10, hydroquinone; systemic or licorice extract (topically), Tego® Cosmo C250, gigawhite, lemon juice extract (topically), emblica extract, etc.) within two weeks;
    • Antiplatelet agents/Anticoagulants (Coumadin, Heparin, Plavix, chronic NSAID use); and/or
    • Psychiatric drugs that in the Investigator's opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.
  18. Individuals who are nursing, pregnant, or planning to become pregnant during the study according to subject self-report.
  19. Individuals having a health condition and/or pre-existing or dormant dermatologic disease on the body (e.g., psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation) that the Investigator or designee deems inappropriate for participation or could interfere with the outcome of the study.
  20. Individuals with a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, prednisone, Remicade, Stelara.) and/or radiation as determined by study documentation.
  21. Individuals with an uncontrolled disease such as asthma, diabetes, hyperthyroidism, medically significant hypertension or hypothyroidism. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc.
  22. Individuals with any planned surgeries, overnight hospitalization, and/or invasive medical procedures during the course of the study.
  23. Individuals who have observable suntan, nevi, excessive hair, etc. or other dermal conditions on the back of the hand that might influence the test results in the opinion of the Investigator or designee.
  24. Individuals who have any condition, which in the opinion of the Investigator makes the patient unable to complete the study per protocol (e.g. patients not likely to avoid other cosmetic treatments to the treatment area; patients not likely to stay in the study for its duration because of other commitments, concomitant conditions, or past history; patients anticipated to be unreliable, or patients who have a concomitant condition that may develop symptoms that might confuse or confound study treatments or assessments).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04559022


Locations
Layout table for location information
United States, Texas
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey Kenkel, MD UT Southwestern
Layout table for additonal information
Responsible Party: Jeffrey M. Kenkel, Chairman, Department of Plastic Surgery, University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier: NCT04559022    
Other Study ID Numbers: STU 2020-0310
First Posted: September 22, 2020    Key Record Dates
Last Update Posted: July 29, 2022
Last Verified: July 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases